Gene Therapy for Cancer Treatment: Past, Present and Future

被引:339
作者
Cross, Deanna [1 ]
Burmester, James K. [1 ]
机构
[1] Marshfield Clin Res Fdn, Ctr Human Genet, 1000 North Oak Ave, Marshfield, WI 54449 USA
关键词
Cancer gene therapy; Gene transfer; Immunotherapy; Oncolytic virotherapy;
D O I
10.3121/cmr.4.3.218
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The broad field of gene therapy promises a number of innovative treatments that are likely to become important in preventing deaths from cancer. In this review, we discuss the history, highlights and future of three different gene therapy treatment approaches: immunotherapy, oncolytic virotherapy and gene transfer. Immunotherapy uses genetically modified cells and viral particles to stimulate the immune system to destroy cancer cells. Recent clinical trials of second and third generation vaccines have shown encouraging results with a wide range of cancers, including lung cancer, pancreatic cancer, prostate cancer and malignant melanoma. Oncolytic virotherapy, which uses viral particles that replicate within the cancer cell to cause cell death, is an emerging treatment modality that shows great promise, particularly with metastatic cancers. Initial phase I trials for several vectors have generated excitement over the potential power of this technique. Gene transfer is a new treatment modality that introduces new genes into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of the cancer. This treatment technique is very flexible, and a wide range of genes and vectors are being used in clinical trials with successful outcomes. As these therapies mature, they may be used alone or in combination with current treatments to help make cancer a manageable disease.
引用
收藏
页码:218 / 227
页数:10
相关论文
共 74 条
[1]
[Anonymous], 2003, BIODRUGS, V17, P216
[2]
[Anonymous], INF CLIN TRAILS HUM
[3]
[Anonymous], 2003, GENETIC ENG NEWS, P6
[4]
[Anonymous], GUID FDA REV STAFF S
[5]
[Anonymous], CHEM YOU GUID SELF H
[6]
[Anonymous], 2006, CANC FACTS FIG 2006
[7]
Science, medicine, and the future - Cellular immunotherapy for cancer [J].
Armstrong, AC ;
Eaton, D ;
Ewing, JC .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7324) :1289-1293
[8]
Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the childhood cancer survivor study [J].
Bassal, M ;
Mertens, AC ;
Taylor, L ;
Neglia, JP ;
Greffe, BS ;
Hammond, S ;
Ronckers, CM ;
Friedman, DL ;
Stovall, M ;
Yasui, YY ;
Robison, LL ;
Meadows, AT ;
Kadan-Lottick, NS .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :476-483
[9]
Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer [J].
Bennett, JJ ;
Delman, KA ;
Burt, BM ;
Mariotti, A ;
Malhotra, S ;
Zager, J ;
Petrowsky, H ;
Mastorides, S ;
Federoff, H ;
Fong, YM .
CANCER GENE THERAPY, 2002, 9 (11) :935-945
[10]
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376